← Back to Patent Explorer
US4950665A Expired / Lapsed US ⏱️ 0.0 years remaining

Phototherapy using methylene blue

Assignee: Oklahoma Medical Research Foundation
•
Filing: 1988-10-28
•
Granted: 1990-08-21
•
Expires: 2008-10-28
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention is a method for using thiazin dyes, especially methylene blue, in combination with light to hydroxylate guanosine or deoxyguanosine at the C8 of the purine ring. The number of guanosines in a nucleic acid strand converted to 8-OH-deoxyguanosine (8-OH-dG) or 8-OH-guanosine (8-OH-G) can be controlled through manipulation of the concentration of methylene blue, light intensity and length of exposure, pH, and buffer strength. The method can be used for the selective mutation or modification of either a DNA or a RNA sequence, or the protein expressed therefrom. The method can also be used in the treatment of viral infectons and in cancer. Methylene blue is FDA approved for topical, i.v., and oral administration. Viruses, bacteria, and cells undergoing rapid DNA synthesis are all inactivated by methylene blue in the presence of light or when irradiated.

Inventors

  • 👤 Robert A. Floyd

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 19:16
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/54; A61M; A61M1/00; A61M1/36; A61M1/3681; A61M1/3683

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 50 words
A composition for modifying nucleic acids in vivo comprising a thiazin dye in combination with a pharmaceutical vehicle, having a concentration to produce a thiazin dye dose concentration of less than or equal to 0.05 mM which is effective to selectively convert guanosine to 8-hydroxyguanosine upon exposure to non-ionizing radition.
Claim 2
Dependent Claim 50 words
A composition for modifying nucleic acids in vivo comprising a thiazin dye in combination with a pharmaceutical vehicle, having a concentration to produce a thiazin dye dose concentration of less than or equal to 0.05 mM which is effective to selectively convert guanosine to 8-hydroxyguanosine upon exposure to non-ionizing radition.
Claim 3
Dependent Claim 14 words
The composition of claim 1 wherein the dose is effective to inactivate a virus.
Claim 4
Dependent Claim 13 words
The composition of claim 1 wherein the dose is effective to kill bacteria.
Claim 5
Dependent Claim 16 words
The composition of claim 1 wherein the dose is effective in the treatment of transformed cells.
Claim 6
Dependent Claim 12 words
The composition of claim 1 wherein the non-ionizing radiation is white light.
Claim 7
Dependent Claim 30 words
The composition of claim 1 wherein the thiazine dye is selected from the group consisting of methylene blue, toludine blue O, azure B, azure A, and combinations and derivatives thereof.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-08-20 1994-02-19 1994-08-21 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-08-20 1998-02-19 1998-08-21 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-08-20 2002-02-19 2002-08-21 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag